At Phase I, (insulin lispro + pramlintide) (Adocia SAS) combines a fast-acting insulin formulation with pramlintide, an amylinomimetic drug marketed for T2D, while the combination of two ultra long-acting peptides, MET-233i, a nutrient-stimulated hormone analogue that targets amylin, with MET-097i, a GLP1RA, form another drug product, (MET-233i + MET-097i) (Metsera Inc)
Its role appears modulatory rather than suppressive, supporting coordinated neural and endocrine timing rather than inducing forced sleep states
Glutathione is a naturally occurring tripeptide built from glutamic acid, cysteine, and glycine
Animal studies using euglycemic clamp techniques, the gold standard for insulin sensitivity assessment, confirmed that chronic AOD-9604 treatment produced no adverse effects on insulin sensitivity
Note: TB-500 is far less studied than full-length Thymosin -4, and the following effects are primarily supported for the parent compound: Actin Binding: Sequesters G-actin monomers, regulating cytoskeletal dynamics essential for cell movement (PMID: 22074294 - Thymosin -4) Cell Migration: Enables endothelial cells, keratinocytes, and other repair cells to migrate to injury sites (PMID: 22074294 - Thymosin -4) Anti-inflammatory: Reduces inflammatory cytokines and promotes resolution of inflammation (PMID: 30116499 - Thymosin -4) Matrix Metalloproteinase Regulation: Modulates tissue remodeling enzymes for proper scar formation (PMID: 16607611 - Thymosin -4) Stem Cell Recruitment: May enhance mobilization of stem cells to damaged areas (PMID: 22074294 - Thymosin -4) Complementary Action: BPC-157 establishes the blood supply (angiogenesis) needed for healing, while TB-500 facilitates the cellular migration and tissue remodeling that follows
Room temperature: the danger zone Room temperature, typically 20 to 25C (68 to 77F), is hostile to reconstituted peptides
